Friday, February 05, 2021 9:25:01 AM
"Voyager Digital Ltd. has provided stakeholders with an update for the following key metrics for the month ended January, 2021, and for the period Feb. 1, 2021, to Feb. 4, 2021.
- Revenue Exceeds US$8.5 Million for the Month of January 2021 and Exceeds US$2.5 Million for the period February 1 to February 4, 2021 -
- Assets Under Management Surpass US$800 Million as of February 4, 2021 -
Preliminary revenue from operations was approximately US$8.5 million for the month of January 2021, up from US$1.7 million in the month of December, 2020. Preliminary revenue from operations for the period February 1, 2021 to February 4, 2021 is estimated to be at approximately US$2.5 million.
Net cash deposits were approximately US$120 million for the month of January, 2021, up from approximately US$30 million for the month of December, 2020. Net cash deposits were approximately US$18 million for the period February 1, 2021 to February 4, 2021.
Assets Under Management (AUM) were approximately US$800 million as of February 4, 2021, up from US$230 million at December 31, 2020, mainly attributable to both the increased in the value of held assets and the net cash deposited on the platform for the period.
Trades per day averaged more than 30,000 for the month ended January 31, 2021, up from an average of approximately 6,500, in December, 2020. Trades per day for the period February 1, 2021 to February 4, 2021 averaged 60,000 trades per day.
New funded accounts were 65,000 for the month of January, 2021, with total funded accounts over 106,000 as of February 4, 2021.
Basic Users on the platform were approximately 440,000 as of February 4, 2021 up from 150,000 as of December 31, 2020.
The value of customer trades for January increased over 5x to US$840 million up from US$150 million in December, 2020. The Company has executed over US$170 million of trades for the period February 1 through February 4, 2021.
All figures are preliminary and unaudited and subject to final adjustment. All amounts are in US dollars, unless otherwise indicated.
"While we believe our recent business metrics reflect the growing interest in the cryptocurrency ecosystem and long-term benefits of our business model, the unprecedented external events over the past week, including decisions made by competitive products, have brought significant upside to our metrics," said Steve Ehrlich, Co-founder and CEO of Voyager. "While we don't expect a repeat of the unprecedented external events of the past few weeks that have served as a catalyst for the recent growth, we anticipate continued meaningful growth in our business, including from the pipeline of approximately 80,000 customers who have signed up and that we are presently onboarding. We remain focused on executing our long-term business plan and expect Voyager will continue to grow the business in a more traditional pattern throughout the balance of 2021. To support this growth, we anticipate increased expenditures in order to materially increase our employee headcount during this period, while also increasing our technology architecture stack in the near-term to accommodate significantly more users."
Recent VYGR News
- Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/26/2024 08:01:00 PM
- Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:00:24 PM
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment • GlobeNewswire Inc. • 02/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:36:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:30:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 08:16:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 08:13:39 PM
- Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:11:54 PM
- Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research • GlobeNewswire Inc. • 02/20/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:03:00 PM
- Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference • GlobeNewswire Inc. • 02/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:34:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:32:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/17/2024 09:20:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2024 08:33:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/17/2024 08:21:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:49:46 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM